Hong Kong Med J 2025;31(Suppl 4):S9-13
Flu-based and PD1-based vaccines for SARS-CoV-2: abridged secondary publication
KY Yuen1, IFN Hung2, H Chen1, Z Chen1
1 Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
2 Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
 
 
  1. In study 1, the intranasally delivered DelNS1-nCoV-receptor-binding domain (RBD) live attenuated influenza virus (LAIV) vaccine for COVID-19 demonstrated safety and immunogenicity among healthy adults who had not previously received a COVID-19 vaccine.
  2. In study 2, the PD1-RBD-DNA vaccine demonstrated safety and immunogenicity among healthy adults who had not previously received a COVID-19 vaccine.
  3. In study 3, the intranasally delivered DelNS1-2019-nCoV-RBD-OPT1 vaccine booster demonstrated safety among healthy individuals who had received two doses of the BNT162b2 vaccine, enhancing both pre-existing cellular and mucosal immune responses.